180 related articles for article (PubMed ID: 32343165)
21. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
23. Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals.
Samonakis DN; Psyllaki M; Pavlaki KI; Drakos E; Kehagias E; Tzardi M; Papadaki HA
Ann Hepatol; 2021; 21():100141. PubMed ID: 31694799
[TBL] [Abstract][Full Text] [Related]
24. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.
Economides MP; Mahale P; Kyvernitakis A; Turturro F; Kantarjian H; Naing A; Hosry J; Shigle TL; Kaseb A; Torres HA
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1235-1241. PubMed ID: 27730654
[TBL] [Abstract][Full Text] [Related]
25. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
26. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
27. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
28. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.
Hosry J; Mahale P; Turturro F; Miranda RN; Economides MP; Granwehr BP; Torres HA
Int J Cancer; 2016 Dec; 139(11):2519-28. PubMed ID: 27501007
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
[TBL] [Abstract][Full Text] [Related]
30. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
31. Identifying Barriers to the Treatment of Chronic Hepatitis C Infection.
Al-Khazraji A; Patel I; Saleh M; Ashraf A; Lieber J; Malik R
Dig Dis; 2020; 38(1):46-52. PubMed ID: 31422405
[TBL] [Abstract][Full Text] [Related]
32. Effect of Direct Acting Antivirals (DAAs) on Myeloid-Derived Suppressor Cells Population in Egyptian Chronic Hepatitis C Virus Patients: A Potential Immunomodulatory Role of DAAs.
Abdulsamad B; Afifi M; Awaad AK; Elbendary W; Mustafa H; Elsherbini B
Viral Immunol; 2023 May; 36(4):259-267. PubMed ID: 36802279
[TBL] [Abstract][Full Text] [Related]
33. Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era.
Devresse A; Delire B; Lazarus JV; Kabamba B; De Meyer M; Mourad M; Buemi A; Darius T; Cambier JF; Goffin E; Jadoul M; Kanaan N
Transplant Proc; 2020 Apr; 52(3):815-822. PubMed ID: 32143864
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses.
Pozzato G; Mazzaro C; Artemova M; Abdurakhmanov D; Grassi G; Crosato I; Mauro E; Ghersetti M; Zorat F; Bomben R; Bulian P; Gattei V
Br J Haematol; 2020 Dec; 191(5):775-783. PubMed ID: 32790920
[TBL] [Abstract][Full Text] [Related]
35. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review.
Sakai H; Miwa T; Ikoma Y; Hanai T; Nakamura N; Imai K; Kitagawa J; Shirakami Y; Kanemura N; Suetsugu A; Takai K; Shiraki M; Shimizu M
Mol Clin Oncol; 2020 Sep; 13(3):1. PubMed ID: 32754315
[TBL] [Abstract][Full Text] [Related]
36. Antiviral therapy in hepatitis C-infected patients prevents relapse of diffuse large B cell lymphoma.
Pellicelli A; Giannelli V; Zoli V; Pellicelli V; Zignego AL
Clin Exp Hepatol; 2018 Sep; 4(3):197-200. PubMed ID: 30324145
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
38. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
39. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
40. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease.
Martin-Cardona A; Horta D; Florez-Diez P; Vela M; Mesonero F; Ramos Belinchón C; García MJ; Masnou H; de la Peña-Negro L; Suarez Ferrer C; Casanova MJ; Durán MO; Peña E; Calvet X; Fernández-Prada SJ; González-Muñoza C; Piqueras M; Rodríguez-Lago I; Sainz E; Bas-Cutrina F; Mancediño Marcos N; Ojeda A; Orts B; Sicilia B; García AC; Domènech E; Esteve M;
Dig Liver Dis; 2024 Mar; 56(3):468-476. PubMed ID: 37770282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
